Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions.
BMJ Case Rep
; 14(2)2021 Feb 01.
Article
en En
| MEDLINE
| ID: mdl-33526518
Immune checkpoint inhibitors (ICIs) are increasingly used to treat certain malignancies due to their higher efficacy compared with conventional chemotherapy. As familiarity with these agents increases, it is becoming apparent that a significant number of patients treated with ICIs experience adverse events. With time, more immune-related adverse events (IRAEs) are being recognised. It is important to be vigilant for IRAEs and recognise that a patient may have multiple IRAEs affecting multiple organ systems. Common cardiovascular adverse events associated with ICIs include myocarditis, arrhythmias and pericarditis. This case report identifies a patient presenting with takotsubo syndrome followed by ketoacidosis (associated with sodium-glucose transport protein 2 (SGLT2) inhibitor) in the setting of combination ipilimumab and nivolumab therapy for metastatic melanoma.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Encefálicas
/
Cetoacidosis Diabética
/
Diabetes Mellitus Tipo 2
/
Cardiomiopatía de Takotsubo
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
/
Inhibidores de Puntos de Control Inmunológico
/
Melanoma
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
BMJ Case Rep
Año:
2021
Tipo del documento:
Article
País de afiliación:
Australia
Pais de publicación:
Reino Unido